167 related articles for article (PubMed ID: 9722289)
21. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Montillo M; Mirto S; Petti MC; Latagliata R; Magrin S; Pinto A; Zagonel V; Mele G; Tedeschi A; Ferrara F
Am J Hematol; 1998 Jun; 58(2):105-9. PubMed ID: 9625576
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
Ferrara F; Melillo L; Montillo M; Leoni F; Pinto A; Mele G; Mirto S
Ann Hematol; 1999 Aug; 78(8):380-4. PubMed ID: 10460353
[TBL] [Abstract][Full Text] [Related]
25. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Carella AM; Cascavilla N; Greco MM; Melillo L; Sajeva MR; Ladogana S; D'Arena G; Perla G; Carotenuto M
Leuk Lymphoma; 2001 Jan; 40(3-4):295-303. PubMed ID: 11426551
[TBL] [Abstract][Full Text] [Related]
26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
27. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
Visani G; Tosi P; Zinzani PL; Manfroi S; Zaccaria A; Testoni N; Lemoli RM; Rosti G; Pelliconi S; Tura S
Br J Haematol; 1994 Feb; 86(2):394-6. PubMed ID: 7515268
[TBL] [Abstract][Full Text] [Related]
28. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
29. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
[TBL] [Abstract][Full Text] [Related]
30. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
31. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia.
Huhmann IM; Watzke HH; Geissler K; Gisslinger H; Jäger U; Knöbl P; Pabinger I; Korninger L; Mannhalter C; Mitterbauer G; Schwarzinger I; Kalhs P; Haas OA; Lechner K
Ann Hematol; 1996 Dec; 73(6):265-71. PubMed ID: 9003155
[TBL] [Abstract][Full Text] [Related]
32. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Blood; 1997 Jun; 89(12):4531-6. PubMed ID: 9192777
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
[TBL] [Abstract][Full Text] [Related]
34. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Giona F; Annino L; Rondelli R; Arcese W; Meloni G; Testi AM; Moleti ML; Amadori S; Resegotti L; Tabilio A; Ladogana S; Fioritoni G; Camera A; Liso V; Leoni P; Mandelli F
Br J Haematol; 1997 Jun; 97(4):896-903. PubMed ID: 9217194
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML).
Leahey A; Kelly K; Rorke LB; Lange B
J Pediatr Hematol Oncol; 1997; 19(4):304-8. PubMed ID: 9256828
[TBL] [Abstract][Full Text] [Related]
36. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
De La Serna J; Francisco Tomás J; Solano C; García de Paredes ML; Campbell J; Grande C; Diaz-Mediavilla J
Leuk Lymphoma; 1997 Apr; 25(3-4):365-72. PubMed ID: 9168446
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
39. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
40. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]